RELMADA THERAPEUTICS INC has a total of 21 patent applications. It decreased the IP activity by 80.0%. Its first patent ever was published in 2009. It filed its patents most often in EPO (European Patent Office), United States and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are IX BIOPHARMA LTD, OCULAR TECH SARL and NEUTEC AR GE SANAYI VE TICARET ANONIM SIRKETI.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 4 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | Hong Kong | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Australia | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Mexico | 1 | |
#10 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Babul Najib | 10 |
#2 | Manfredi Paolo L | 5 |
#3 | Inturrisi Charles E | 5 |
#4 | Fai Jim | 4 |
#5 | Kao Huai-Hung D | 4 |
#6 | Jim Fai | 2 |
#7 | Rehni Ashish Kumar | 2 |
#8 | Kao Huai-Hung | 1 |
#9 | Kao Huai Hung D | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020159901A1 | Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist | |
CN109982690A | Wear-resisting opioid formulation | |
AU2016259348A1 | Dermal pharmaceutical compositions of 1-Methyl-2',6' pipecoloxylidide and method of use | |
EP2557924A1 | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use | |
EP2448406A1 | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use | |
EP2405754A1 | Modified release pharmaceutical compositions of buprenorphine |